Searle To Discuss Adding Celebrex 13-Month Safety Data To Label With FDA
Executive Summary
Searle plans to approach FDA with data from a 13-month trial comparing the ulcer incidence for Celebrex to other nonsteroidal anti-inflammatory drugs, seeking a label change for the COX-2 inhibitor.
You may also be interested in...
Pharmacia To Publish Full 12-Month Data From CLASS Study Of Celebrex
Pharmacia is preparing to publish the full 12-month data from the Celebrex CLASS GI outcomes study.
Pharmacia To Publish Full 12-Month Data From CLASS Study Of Celebrex
Pharmacia is preparing to publish the full 12-month data from the Celebrex CLASS GI outcomes study.
Celebrex, Vioxx GI Safety Data To Be Reviewed By FDA Committee Feb. 7-8
Applications to modify the NSAID class gastrointestinal safety labeling for the COX-2 inhibitors Celebrex and Vioxx will be reviewed by FDA's Arthritis Advisory Committee Feb. 7-8.